Paris, France
Rene Lafont, Stanislas Veillet
2006
Public company
EPA:ALBPS
IPO
14.9
CM-CIC Capital Prive, Seventure Partners, AGORANOV
Altered intercellular communication
Sarcopenia, Duchenne Muscular Dystrophy, Dry age-related Macular Degeneration, Stargardt's Disease
small molecule drugs
Phase 2 Trials
Sarconeos. (BIO101), Macuneos (BIO201)
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.